FDA OKs Immune-Boosting Drug for Advanced Bladder Cancer
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
U.S. regulators have approved a new drug that harnesses the immune system to treat bladder cancer that has spread after chemotherapy or surgery. The FDA approved Imfinzi for advanced bladder cancer, along with a companion diagnostic test for identifying which patients are most likely to benefit from it.

Imfinzi, also known as durvalumab, is part of a new generation of drugs that stimulate the immune system to help fight cancer. British drugmaker AstraZeneca PLC, which developed the drug, is testing it for several other cancers. The average monthly list price for Imfinzi is roughly $15,000, but varies with the patient's weight, according to AstraZeneca. It's given by IV, usually every two weeks.

Until recently, treatment options were limited to chemotherapy, radiation or surgery.

http://www.foxbusiness.com/features/2017/05/01/fda-oks-immune-boosting-drug-for-advanced-bladder-cancer.html
Preview
Like
Comment
Share